Kineta, Inc. (KANT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kineta, Inc. (KANT) has a cash flow conversion efficiency ratio of 0.153x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($-7.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kineta, Inc. net assets for net asset value and shareholders' equity analysis.
Kineta, Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kineta, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kineta, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
N/A |
|
Azincourt Uranium Inc
V:AAZ
|
-0.089x |
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Crown Confectionery Co Ltd Pref
KO:26490K
|
0.015x |
|
Inotiv Inc
NASDAQ:NOTV
|
-0.050x |
|
Aro Granite Industries Limited
NSE:AROGRANITE
|
0.086x |
|
TRU PRECIOUS METALS CORP.
F:706
|
0.050x |
|
Trinitan Metals and Minerals
JK:PURE
|
0.047x |
Annual Cash Flow Conversion Efficiency for Kineta, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Kineta, Inc. from 2020 to 2023. For the full company profile with market capitalisation and key ratios, see Kineta, Inc. (KANT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.06 Million | $-16.21 Million | -5.299x | -27.26% |
| 2022-12-31 | $4.57 Million | $-19.03 Million | -4.164x | -378.69% |
| 2021-12-31 | $-11.95 Million | $-17.85 Million | 1.494x | +1502.09% |
| 2020-12-31 | $-21.55 Million | $2.30 Million | -0.107x | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more